GRTSQ (Gritstone Bio) Debt-to-Asset : 0.72 (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio Debt-to-Asset?

Gritstone Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $7.16 Mil. Gritstone Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $95.34 Mil. Gritstone Bio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $142.54 Mil. Gritstone Bio's debt to asset for the quarter that ended in Jun. 2024 was 0.72.

Gritstone Bio Debt-to-Asset Historical Data

The historical data trend for Gritstone Bio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio Debt-to-Asset Chart

Gritstone Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.13

0.11

0.10

0.17

0.59

Gritstone Bio Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.43	0.51	0.59	0.75	0.72

Competitive Comparison of Gritstone Bio's Debt-to-Asset

For the Biotechnology subindustry, Gritstone Bio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gritstone Bio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gritstone Bio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's Debt-to-Asset falls into.

Gritstone Bio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Gritstone Bio's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.904	+	97.871)	/	177.769
	=	0.59

Gritstone Bio's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.159	+	95.335)	/	142.542
	=	0.72

Gritstone Bio (OTCPK:GRTSQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Gritstone Bio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Gritstone Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (OTCPK:GRTSQ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

2JQ:Germany

Address

5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608

Website

https://gritstonebio.com

Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.

Executives

Andrew R Allen	director, officer: President and CEO	2525 28TH STREET, SUITE 200, BOULDER CO 80301
Matthew Hawryluk	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Erin Jones	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Vassiliki Economides	officer: See Remarks	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Jooss	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Lawrence Corey	director	C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi	director	C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher	director	C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes	director	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James Cho	officer: Chief Accounting Officer	C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104